Article Details
Retrieved on: 2018-03-11 21:54:57
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>Cadent Therapeutics, a precision neuroscience company developing novel medicines to restore movement and cognitive function in patients with neurological and psychiatric disease, today announced the initiation of a Phase 1 clinical study for its lead product candidate CAD-1883. The compound is a ...</div>
Article found on:
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here